Volume 82, Issue 1 pp. 1-8
Coronary Artery Disease

Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical, and cost-utilization outcomes

Dimitri Karmpaliotis MD

Dimitri Karmpaliotis MD

Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309

Search for more papers by this author
Nicholas Lembo MD

Nicholas Lembo MD

Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309

Search for more papers by this author
Anna Kalynych MD

Anna Kalynych MD

Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309

Search for more papers by this author
Harold Carlson MD

Harold Carlson MD

Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309

Search for more papers by this author
William L. Lombardi MD

William L. Lombardi MD

PeaceHealth St. Joseph Medical Center, 29779 Squalicum Parkway Suite 101, Bellingham, WA 98225

Conflict of interest: Dr. Karmpaliotis and Lembo have received consulting honoraria from Abbott Vascular, and Bridgepoint Medical. Dr. Lombardi receives consulting honoraria from Abbott Vascular, Bridgepoint Medical, Medtronic CardioVascular, and Terumo Medical. ; and has equity in Bridgepoint Medical. Dr. Kandzari receives research/grant support and consulting honoraria from Abbott Vascular, Medtronic CardioVascular, and Micell Technologies. All other authors have no related disclosures.

Search for more papers by this author
Chad N. Anderson MHA

Chad N. Anderson MHA

Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309

Search for more papers by this author
Sarah Rinehart MD

Sarah Rinehart MD

Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309

Search for more papers by this author
Ben Kirkland BS

Ben Kirkland BS

Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309

Search for more papers by this author
Kathie C. Shemwell RN

Kathie C. Shemwell RN

Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309

Search for more papers by this author
David E. Kandzari MD

Corresponding Author

David E. Kandzari MD

Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309

Conflict of interest: Dr. Karmpaliotis and Lembo have received consulting honoraria from Abbott Vascular, and Bridgepoint Medical. Dr. Lombardi receives consulting honoraria from Abbott Vascular, Bridgepoint Medical, Medtronic CardioVascular, and Terumo Medical. ; and has equity in Bridgepoint Medical. Dr. Kandzari receives research/grant support and consulting honoraria from Abbott Vascular, Medtronic CardioVascular, and Micell Technologies. All other authors have no related disclosures.

Correspondence to: David E. Kandzari, MD, Suite 300 Piedmont Heart Institute, 275 Collier Road, Atlanta, Georgia 30309. E-mail: [email protected]Search for more papers by this author
First published: 11 April 2013
Citations: 104

Abstract

Background

Development of a specialized chronic total coronary occlusion (CTO) revascularization program attentive to procedural guidelines, quality oversight, and cost/resource utilization has not been described.

Methods

A single-center CTO interventional program was initiated with requirements including: extensive didactic training, on-site proctorship, routine determination of case appropriateness, adherence to procedural safety guidelines, and a 2-operator/case approach. Clinical and angiographic characteristics, procedural outcomes, in-hospital clinical events, and cost/resource utilization were examined.

Results

Among 145 patients, 160 consecutive CTO revascularization procedures were attempted between October 2009 and December 2010. Selected procedural and technical characteristics included: bilateral femoral access, 90.0%; planned retrograde guidewire placement, 37.5%; re-entry catheter, 10.0%; reattempt, 10.6%; fluoroscopic time, 67.4 ± 45.5 min; contrast volume, 403 ± 215 mL. Average stent number and total stent length per CTO vessel were 2.6 ± 1.1 and 64.7 ± 30.7 mm, respectively. Overall CTO success rate was 85.6% (137/160). In-hospital adverse outcomes included: death 0.6%; emergency bypass surgery, 0.6%; tamponade, 0.6%; myocardial infarction, 1.9%; transient nephropathy, 1.2%. Compared with patients undergoing non-CTO PCI, procedural and total cost per patient were significantly higher among the CTO cohort despite overall similar contribution margins ($5,173 ± 12,052 versus $5,730 ± 8,958, P = 0.58).

Conclusions

Following initiation of a dedicated program with implementation of quality and performance guidelines, complex CTO revascularization may be safely performed with outcomes comparable with reports from established centers. Despite higher resource utilization, CTO revascularization is associated with a positive contribution margin. Requirement of educational and performance standards, mentorship from experts, consensus review for appropriateness and provision of catheterization laboratory policies may represent a model for program development. © 2013 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.